<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03360747</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 703802-CS3</org_study_id>
    <nct_id>NCT03360747</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Familial Chylomicronemia Syndrome (FCS)</brief_title>
  <official_title>A Phase 2 Open-Label Study to Assess the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AKCEA-ANGPTL3-LRX (ISIS 703802) Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akcea Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Akcea Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3-LRX for
      reduction of triglyceride (TG) levels in patients with Familial Chylomicronemia Syndrome
      (FCS) .
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in fasting TG</measure>
    <time_frame>3 months</time_frame>
    <description>Percent change and change from baseline to Month 3 in fasting TG will be summarized.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting ANGPTL3</measure>
    <time_frame>3 months</time_frame>
    <description>Percent change and change from baseline to Month 3 will be summarized in fasting ANGPTL3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting lipid measurements</measure>
    <time_frame>3 months</time_frame>
    <description>Percent change and change from baseline to Month 3 will be summarized</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3</enrollment>
  <condition>Familial Chylomicronemia Syndrome</condition>
  <condition>Lipoprotein Lipase Deficiency</condition>
  <condition>Hyperlipoproteinemia Type 1</condition>
  <arm_group>
    <arm_group_label>AKCEA-ANGPTL3-LRX Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AKCEA-ANGPTL3-LRX</intervention_name>
    <description>Single open-label cohort</description>
    <arm_group_label>AKCEA-ANGPTL3-LRX Dose 1</arm_group_label>
    <other_name>ISIS 703802</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Genetically confirmed Chylomicronemia Syndrome

          -  Fasting triglycerides ≥ 750 mg/dL (8.4 mmol/L) at Screening

        Exclusion Criteria:

          -  Diabetes mellitus if newly diagnosed or if HbA1c ≥ 9.0%

          -  Active pancreatitis within 2 weeks of screening

          -  Acute Coronary Syndrome within 6 months of screening

          -  Major surgery within 3 months of screening

          -  Treatment with Glybera therapy within 2 years of screening

          -  Previous treatment with AKCEA-ANGPTL3-LRX

          -  Have any other conditions in the opinion of the investigator which could interfere
             with the patient participating in or completing the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Akcea Therapeutics</last_name>
    <phone>617-207-0289</phone>
    <email>clinicalstudies@akceatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2W 1R7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2017</study_first_submitted>
  <study_first_submitted_qc>December 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2017</study_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Familial Lipoprotein Lipase Deficiency</keyword>
  <keyword>Hyperlipoproteinemias</keyword>
  <keyword>Familial Hyperlipoproteinemia Type 1</keyword>
  <keyword>Hyperlipoproteinemia Type I</keyword>
  <keyword>Hyperchylomicronemia, Familial</keyword>
  <keyword>Lipoprotein Lipase Deficiency, Familial</keyword>
  <keyword>Hyperlipidemias</keyword>
  <keyword>Dyslipidemias</keyword>
  <keyword>Lipid Metabolism Disorders</keyword>
  <keyword>Lipid Metabolism, Inborn Errors</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Metabolism, Inborn Errors</keyword>
  <keyword>Genetic Diseases, Inborn</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type I</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

